Triple

T2370981
Position Surface form Disambiguated ID Type / Status
Subject Herceptin E46088 entity
Predicate isIndicatedInCombinationWith P4791 FINISHED
Object pertuzumab
Pertuzumab is a monoclonal antibody used in targeted therapy for HER2-positive breast cancer, often administered alongside trastuzumab and chemotherapy.
 E263659 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: pertuzumab | Statement: [Herceptin, isIndicatedInCombinationWith, pertuzumab]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: pertuzumab
Context triple: [Herceptin, isIndicatedInCombinationWith, pertuzumab]
  • A. Herceptin
    Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
  • B. Alimta
    Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
  • C. Tecentriq
    Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
  • D. Avastin
    Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
  • E. Verzenio
    Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: pertuzumab
Triple: [Herceptin, isIndicatedInCombinationWith, pertuzumab]
Generated description
Pertuzumab is a monoclonal antibody used in targeted therapy for HER2-positive breast cancer, often administered alongside trastuzumab and chemotherapy.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: pertuzumab
Target entity description: Pertuzumab is a monoclonal antibody used in targeted therapy for HER2-positive breast cancer, often administered alongside trastuzumab and chemotherapy.
  • A. Herceptin
    Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
  • B. Alimta
    Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
  • C. Tecentriq
    Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
  • D. Avastin
    Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
  • E. Verzenio
    Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69a88a145268819083e2736cb835c696 completed March 4, 2026, 7:37 p.m.
NER Named-entity recognition batch_69abd0d813dc8190aa331cdca0b75eca completed March 7, 2026, 7:16 a.m.
NED1 Entity disambiguation (via context triple) batch_69aeb3c81430819081654a90df17c5c0 completed March 9, 2026, 11:49 a.m.
NEDg Description generation batch_69aeb4a5011c8190bda6c487dab73131 completed March 9, 2026, 11:53 a.m.
NED2 Entity disambiguation (via description) batch_69aeb59d0e5c819080bf5b34946b68ac completed March 9, 2026, 11:57 a.m.
Created at: March 4, 2026, 7:56 p.m.